MedTrace Logo

Risk Stratification Using MEESSI-AHF Scale in ED and Impact on AHF Outcomes

NCT05919225 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3200

Last updated 2024-02-28

No results posted yet for this study

Summary

Evaluate the impact the application of the MESSI-AHF scale (a risk stratification scale specifically derived and validated in patients diagnosed with acute heart failure, AHF) in decision making (admission vs. discharge) by emergency physicians in emergency departments (ED) and its potential impact on on the short-term prognosis of patients with AHF.

Conditions

  • Acute Heart Failure
  • Emergencies

Interventions

PROCEDURE

Risk stratification before decision-making about patient hospitalization or discharge

Once AHF has been diagnosed at ED, and before decision-making about hospitalize/discharge home is taken, physicians will objectively measure the severity of decompensation, based on risk of 30-day death using MEESSI scale. As result, patient can be allocated to low, intermediate, high or very-high risk. For patients classified as low-risk, the propocol recommendation will be discharge patient to home. For patients classified as increased risk (i.e., intermediate, high or very-high risk categories), the protocol recommendation will be to hospitalize patient. Nonetheless, final decission will be left to emergency physician, and overruling (disposition against recommendation) will be allowed.

Sponsors & Collaborators

  • Instituto de Salud Carlos III

    collaborator OTHER_GOV

  • Hospital Clinic of Barcelona

    lead OTHER

Principal Investigators

  • Oscar Miro, PhD · Hospital CLinic, Barcelona, Spain

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-27
Primary Completion
2024-04-30
Completion
2024-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05919225 on ClinicalTrials.gov